Healthcare, Regulatory and Reimbursement Landscape – Denmark by rgunnam

VIEWS: 10 PAGES: 2

More Info
									Healthcare, Regulatory and Reimbursement Landscape – Denmark

Denmark Healthcare Market Bouncing Back After Recession

The Danish healthcare market is showing healthy signs of recovery following the crippling global
financial crisis of 2008, says the latest report from business intelligence providers GlobalData.

The firm’s new report* predicts Denmark’s pharmaceuticals sector to grow from US$4 billion in 2011 to
US$7.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 6.9%. This expected
growth follows three years of shrinking pharmaceutical revenue for the north European country.

Additionally, Denmark’s medical devices sector is forecast to grow from 2011’s total of US$1.4 billion, to
US$2.3 billion by the end of the decade.

GlobalData attributes Denmark’s healthcare industry expansion to a growing elderly population: 16.8%
of Danish citizens were 65 years old or older in 2011, with this proportion reaching 19.6% by 2020,
according to Statistics Denmark.

Additionally, Denmark’s pharmaceutical market will be bolstered by investment in innovative products.
Novo Nordisk, along with other Danish firms such as LEO Pharma and Lundbeck, invest 15%–20% of their
revenues in R&D. Furthermore, the country’s biotechnology sector spent approximately US$5.2 billion
on R&D in 2011 – the second highest in Europe.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?CompanyID=dcstc&ID=Healthcare-
Regulatory-and-Reimbursement-Landscape-
Denmark&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare

However, Denmark is not lacking in obstacles to overcome. At 25%, Value Added Tax (VAT) in the
country is higher than that of other countries in the EU (UK and the
 Netherlands have 20% and 19% respectively), and wages in Denmark are higher than
all other nations in the Organization for Economic Co-operation and Development (OECD), with the
exception of Norway. Consequently, manufacturing and sales costs are substantial in Denmark.

This report is an essential source of information and analysis on Denmark`s healthcare, regulatory and
reimbursement landscape.

This report was built using data and information sourced from proprietary databases, primary and
secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients
make better, more informed decisions every day. Our research and analysis is based on the expert
knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry
insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business
intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Healthcare-Regulatory-and-Reimbursement-
Landscape-Denmark&CompanyID=dcstc

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe:                +44 207 753 4299
                       +44 1204 543 533
Asia Pacific:          +91 40 6616 6782

								
To top